SG Americas Securities LLC acquired a new stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,931 shares of the medical instruments supplier’s stock, valued at approximately $584,000.
Other large investors also recently made changes to their positions in the company. Dark Forest Capital Management LP purchased a new position in Mesa Laboratories during the second quarter valued at $71,000. Harbor Investment Advisory LLC purchased a new position in Mesa Laboratories during the third quarter valued at $97,000. Mutual of America Capital Management LLC raised its stake in Mesa Laboratories by 6.8% during the second quarter. Mutual of America Capital Management LLC now owns 694 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 44 shares during the last quarter. M&T Bank Corp purchased a new position in Mesa Laboratories during the third quarter valued at $232,000. Finally, Ergoteles LLC bought a new stake in shares of Mesa Laboratories in the 2nd quarter worth $244,000. Institutional investors and hedge funds own 91.51% of the company’s stock.
A number of research firms have commented on MLAB. Zacks Investment Research lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. TheStreet lowered Mesa Laboratories from a “b-” rating to a “c” rating in a report on Friday, January 7th.
Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Thursday, November 4th. The medical instruments supplier reported $1.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.60. Mesa Laboratories had a return on equity of 6.17% and a net margin of 3.56%. The company had revenue of $35.84 million during the quarter, compared to analyst estimates of $34.95 million. On average, equities research analysts forecast that Mesa Laboratories, Inc. will post 6.49 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 15th. Investors of record on Monday, February 28th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.22%. The ex-dividend date is Friday, February 25th. Mesa Laboratories’s payout ratio is currently 68.82%.
In related news, CFO John Sakys sold 2,000 shares of Mesa Laboratories stock in a transaction on Wednesday, October 20th. The stock was sold at an average price of $309.86, for a total value of $619,720.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Gregory Dinoia sold 280 shares of the company’s stock in a transaction dated Monday, November 8th. The stock was sold at an average price of $323.72, for a total value of $90,641.60. The disclosure for this sale can be found here. Insiders sold 15,227 shares of company stock valued at $4,791,041 in the last ninety days. 5.10% of the stock is currently owned by corporate insiders.
Mesa Laboratories Profile
Mesa Laboratories, Inc engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development.
Further Reading: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.